How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Aptamers for Treatment and Diagnosis of Autoantibody-based dilated Cardiomyopathy

Organization name

ascenion GmbH

Profile

Challenge

Cardiovascular diseases still are a major cause of death despite the enormous efforts in cardiac therapy. Several factors may influence the onset and progression of the disease, and consequently, many forms of cardiovascular diseases can be observed. In approximately 70% of idiopathic dilated cardiomyopathy (DCM) patients and in nearly 100% of patients with Chagas’ cardiomyopathy and peripartum cardiomyopathy, antibodies to the beta1- adrenergic receptor are detected. With a prevalence of 36 cases per 100,000 people for idiopathic DCM, and a prevalence of 1,000 cases per 100,000 people (Latin America) for Chagas’ cardiomyopathy, reliable means for auto-antibody diagnostics and cause-specific therapies are required.

Technology

The technology relates to novel high-affinity aptamers specifically binding to auto-antibodies directed against the second extracellular loop of human beta1-adrenergic receptors. Due to the strong and specific binding, the aptamers can be used in a bioassay for antibody detection, enabling therapeutic decisions for depletion of pathogenic auto-antibodies by unspecific or specific immune aphaeresis. Furthermore, the aptamers have therapeutic potential for treatment of idiopatic DCM, Chagas’ cardiomyopathy and peripartum cardiomyopathy through selective inhibition of beta1-adrenergic auto-antibodies.

Commercial Opportunity

In-licensing and/or collaboration opportunity for development of a diagnostic tool or a novel therapeutic approach.

Patent Situation

A European patent application hold by Charité – Universitätsmedizin Berlin, Max-Delbrück-Centrum für Molekulare Medizin, and Aptares AG is pending (unpublished).

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries